Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 3M COMMM · Entity 1275 | Director · Chairman of the Board | February 03, 2025 | February 18, 2025 |
| ABBOTT LABORATORIESABT · Entity 2314 | Director | September 30, 2026 | October 03, 2026 |
| Waystar Holding Corp.WAY · Entity 1420 | Director | June 03, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
3M CO
Report date February 03, 2025 · Filed February 18, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 193,397.2991 |
Reported balance
After 2025-02-03 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-02-03 · Tax withholding · Disposed 8,600 · Balance 193,397.2991 F1: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld. |
Filing footnotes · ownership attribution and instrument terms
F1: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld.
ABBOTT LABORATORIES
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Equivalent UnitsSEC Table II · derivative / convertible security | Direct | 7,166 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 381 · Balance 7,166 F1: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. |
Filing footnotes · ownership attribution and instrument terms
F1: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
Waystar Holding Corp.
Report date June 03, 2026 · Filed September 25, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,580 |
Reported balance
After 2026-06-03 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 10,446 · Balance 15,580 F1: Reflects a grant of restricted stock units ("RSUs") which vest on the earlier of (i) June 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders following the grant date. Each RSU represents a contingent right to receive one share of Common Stock upon settlement. This amended Form 4 is being filed solely to correct the number of RSUs granted from 9,303 to 10,446. F2: Includes unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units ("RSUs") which vest on the earlier of (i) June 1, 2027 and (ii) the first regularly scheduled annual meeting of the stockholders following the grant date. Each RSU represents a contingent right to receive one share of Common Stock upon settlement. This amended Form 4 is being filed solely to correct the number of RSUs granted from 9,303 to 10,446.
F2: Includes unvested RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 24, 2025 Filed Jan 27, 2025 13:57 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 9,100 | $150.04 | $1,365,318.50 |
DisclosureSEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 7 Roman Michael F · CIK 0001577544 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,923.0713 Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 13:57 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 200 | $150.03 | $30,005.00 |
DisclosureSEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 6 Roman Michael F · CIK 0001577544 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,023.0713 Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 13:57 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 947 | $150.02 | $142,068.94 |
DisclosureSEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 5 Roman Michael F · CIK 0001577544 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,223.0713 Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 13:57 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 8,321 | $150.01 | $1,248,233.21 |
DisclosureSEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 4 Roman Michael F · CIK 0001577544 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,170.0713 Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 13:57 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 100 | $150.01 | $15,000.50 |
DisclosureSEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 3 Roman Michael F · CIK 0001577544 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,491.0713 Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 13:57 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 25,403 | $150.00 | $3,810,450.00 |
DisclosureSEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 2 Roman Michael F · CIK 0001577544 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,591.0713 Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 13:57 UTC | 3M CO MMM · Entity 1275 | Exercise / conversionCommon Stock | 45,276 | $146.05 | $6,612,559.80 |
DisclosureSEC source: 0001127602-25-001991 · form4.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,994.0713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 311 | $113.11 | $35,177.21 |
DisclosureSEC source: 0001415889-25-000575 · form4-01032025_100102.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,670 Underlying: Common Shares · 311 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2024 Filed Oct 1, 2024 21:39 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 309 | $114.01 | $35,229.09 |
DisclosureSEC source: 0001415889-24-024240 · form4-10012024_091021.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,338 Underlying: Common Shares · 309 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 12:02 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 482 | $123.48 | $59,517.36 |
DisclosureSEC source: 0001127602-24-021839 · form4.xml · nonDerivative · entry 4 Roman Michael F · CIK 0001577544 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,035.5568 F1 · balance_after: Includes dividend share equivalents, accrued quarterly, pursuant to 3M's Deferred Compensation Plan. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 12:02 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 443 | $123.47 | $54,697.21 |
DisclosureSEC source: 0001127602-24-021839 · form4.xml · nonDerivative · entry 3 Roman Michael F · CIK 0001577544 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,517.5568 Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 12:02 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 611 | $123.46 | $75,434.06 |
DisclosureSEC source: 0001127602-24-021839 · form4.xml · nonDerivative · entry 2 Roman Michael F · CIK 0001577544 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,960.5568 Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 12:02 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 4,139 | $123.45 | $510,959.55 |
DisclosureSEC source: 0001127602-24-021839 · form4.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,571.5568 Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:30 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 339 | $103.91 | $35,225.49 |
DisclosureSEC source: 0001415889-24-018914 · form4-07022024_080740.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,009 Underlying: Common Shares · 339 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| May 03, 2024 Filed May 6, 2024 22:56 UTC | 3M CO MMM · Entity 1275 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 316,644 | $97.10 Strike: $97.15 | $30,746,132.40 |
DisclosureSEC source: 0001127602-24-014349 · form4.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director · Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,644 Underlying: Common Stock · 316,644 shares Expires 2034-05-02 F1 · derivative.exercise_date: The stock option will vest and become exercisable in a series of three equal annual installments beginning on February 6, 2025. Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-011799 · form4-04302024_100430.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,843 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 22:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 310 | $113.66 | $35,234.60 |
DisclosureSEC source: 0001415889-24-009863 · form4-04022024_100413.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,650 Underlying: Common Shares · 310 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 19:40 UTC | 3M CO MMM · Entity 1275 | Tax withholdingCommon Stock | 601 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003525 · form4.xml · nonDerivative · entry 2 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,711.2602 F4 · shares: The number of shares withheld for taxes was estimated and will be revised by amendment if necessary. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 19:40 UTC | 3M CO MMM · Entity 1275 | GrantCommon Stock | 24,954.272 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003525 · form4.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,312.2602 F1 · shares: Represents shares of 3M common stock that will be delivered pursuant to the terms of a performance share award made to the reporting person on March 1, 2021. The performance-based vesting requirements applicable to such award were satisfied on the date reported in Column 2 above, which represents the date on which the level of performance attained was certified. The reporting person previously elected to defer receipt of the shares and will not have voting or investment powers with respect to such shares until they are issued. F2 · balance_after: Includes dividend share equivalents, accrued quarterly, pursuant to 3M's Deferred Compensation Plan. F3 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan. Read SEC document |
| February 05, 2024 Filed Feb 15, 2024 19:38 UTC Amendment | 3M CO MMM · Entity 1275 | Tax withholdingCommon Stock | 791.403 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-005173 · form4a.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,520.8572 F1 · shares: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 320 | $110.07 | $35,222.40 |
DisclosureSEC source: 0001415889-24-000362 · form4-01032024_100152.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,324 Underlying: Common Shares · 320 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 22:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 363 | $96.85 | $35,156.55 |
DisclosureSEC source: 0001415889-23-013949 · form4-10032023_101048.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,988 Underlying: Common Shares · 363 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 15:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 316 | $109.02 | $34,450.32 |
DisclosureSEC source: 0001104659-23-077924 · tm2320556-4_4seq1.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,612 Underlying: Common Shares · 316 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| April 28, 2023 Filed May 3, 2023 00:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007138 · form4-05032023_120557.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,977 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F2 · balance_after: Includes 60 shares that were acquired before Mr. Roman became an Abbott director and were not previously reported. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 23:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 325 | $101.26 | $32,909.50 |
DisclosureSEC source: 0001415889-23-006151 · form4-04042023_110437.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,285 Underlying: Common Shares · 325 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 22:11 UTC | 3M CO MMM · Entity 1275 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 269,995 | $0.00 Strike: $116.90 | $0.00 |
DisclosureSEC source: 0001127602-23-004044 · form4.xml · derivative · entry 3 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,995 Underlying: Common Stock · 269,995 shares Expires 2033-02-07 F5 · derivative.exercise_date: The stock option will vest and become exercisable in a series of three equal installments on each of the first, second and third anniversary of the grant date. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 22:11 UTC | 3M CO MMM · Entity 1275 | Tax withholdingCommon Stock | 844.743 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004044 · form4.xml · nonDerivative · entry 2 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,140.4576 F4 · shares: The number of shares withheld for taxes was estimated and will be revised by amendment if necessary. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 22:11 UTC | 3M CO MMM · Entity 1275 | GrantCommon Stock | 35,281.349 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004044 · form4.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,985.2006 F1 · shares: Represents shares of 3M common stock that will be delivered pursuant to the terms of a performance share award made to the reporting person on March 1, 2020. The performance-based vesting requirements applicable to such award were satisfied on the date reported in Column 2, which represents the date on which the level of performance attained was certified. The reporting person previously elected to defer receipt of the shares and will not have voting or investment powers with respect to such shares until they are issued. F2 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan. F3 · balance_after: Includes dividend share equivalents, accrued quarterly, pursuant to 3M's Deferred Compensation Plan. Read SEC document |
| February 06, 2023 Filed Feb 21, 2023 13:59 UTC Amendment | 3M CO MMM · Entity 1275 | Tax withholdingCommon Stock | 1,139.996 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006072 · form4a.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,845.2046 F1 · shares: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 23:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 300 | $109.79 | $32,937.00 |
DisclosureSEC source: 0001415889-23-000437 · form4-01042023_110104.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,949 Underlying: Common Shares · 300 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 21:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 341 | $96.76 | $32,995.16 |
DisclosureSEC source: 0001415889-22-010265 · form4-10042022_021057.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,641 Underlying: Common Shares · 341 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 20:26 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 303 | $108.65 | $32,920.95 |
DisclosureSEC source: 0001415889-22-007173 · form4-07012022_010742.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,295 Underlying: Common Shares · 303 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| May 03, 2022 Filed May 4, 2022 14:49 UTC | 3M CO MMM · Entity 1275 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 10,610 | $0.00 Strike: $101.49 | $0.00 |
DisclosureSEC source: 0001127602-22-013149 · form4.xml · derivative · entry 3 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,610 shares Expires 2023-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 4, 2022 14:49 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 10,610 | $146.21 | $1,551,288.10 |
DisclosureSEC source: 0001127602-22-013149 · form4.xml · nonDerivative · entry 2 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,360.7475 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 30, 2021. F2 · balance_after: Includes dividend share equivalents, accrued quarterly, pursuant to 3M's Deferred Compensation Plan. F3 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan. Read SEC document |
| May 03, 2022 Filed May 4, 2022 14:49 UTC | 3M CO MMM · Entity 1275 | Exercise / conversionCommon Stock | 10,610 | $101.49 | $1,076,808.90 |
DisclosureSEC source: 0001127602-22-013149 · form4.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,970.7475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 30, 2021. Read SEC document |
| April 29, 2022 Filed May 3, 2022 22:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,602 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-004553 · form4-05032022_030519.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,101 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 278 | $118.36 | $32,904.08 |
DisclosureSEC source: 0001415889-22-003592 · form4-04012022_020434.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 987 Underlying: Common Shares · 278 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| February 08, 2022 Filed Feb 9, 2022 23:45 UTC | 3M CO MMM · Entity 1275 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 217,083 | $0.00 Strike: $162.41 | $0.00 |
DisclosureSEC source: 0001127602-22-004050 · form4.xml · derivative · entry 3 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,083 Underlying: Common Stock · 217,083 shares Expires 2032-02-06 F5 · derivative.exercise_date: The stock option will vest and become exercisable in a series of three equal installments on each of the first, second and third anniversary of the grant date. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 23:45 UTC | 3M CO MMM · Entity 1275 | Tax withholdingCommon Stock | 558.862 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004050 · form4.xml · nonDerivative · entry 2 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,804.0188 F4 · shares: The number of shares withheld for taxes was estimated and will be revised by amendment if necessary. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 23:45 UTC | 3M CO MMM · Entity 1275 | GrantCommon Stock | 23,427.52 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004050 · form4.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,362.8808 F1 · shares: Represents shares of 3M common stock that will be delivered pursuant to the terms of a performance share award made to the reporting person on March 1, 2019. The performance-based vesting requirements applicable to such award were satisfied on the date reported in Column 2 above, which represents the date on which the level of performance attained was certified. The reporting person previously elected to defer receipt of the shares and will not have voting or investment powers with respect to such shares until they are issued. F2 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan. F3 · balance_after: Includes dividend share equivalents, accrued quarterly, pursuant to 3M's Deferred Compensation Plan. Read SEC document |
| February 07, 2022 Filed Feb 22, 2022 14:34 UTC Amendment | 3M CO MMM · Entity 1275 | Tax withholdingCommon Stock | 754.036 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005844 · form4a.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,608.8448 F1 · shares: The number of shares previously reported as being withheld for the payment of taxes was estimated. This amendment is being filed to update the Form 4 with the actual number of shares withheld. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 234 | $140.74 | $32,933.16 |
DisclosureSEC source: 0001415889-22-000238 · form4-01042022_020103.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705 Underlying: Common Shares · 234 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 21:41 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 279 | $118.13 | $32,958.27 |
DisclosureSEC source: 0001415889-21-004715 · form4-10042021_021035.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469 Underlying: Common Shares · 279 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| July 30, 2021 Filed Jan 6, 2022 20:05 UTC | 3M CO MMM · Entity 1275 | GiftCommon Stock | 1,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-001070 · form5.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,860.7834 Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantStock Equivalent Units · Derivative | 189 | $115.93 | $21,910.77 |
DisclosureSEC source: 0001415889-21-003423 · form4-07022021_020728.xml · derivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189 Underlying: Common Shares · 189 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares. Read SEC document |
| May 03, 2021 Filed May 4, 2021 14:45 UTC | 3M CO MMM · Entity 1275 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 9,747 | $0.00 Strike: $87.89 | $0.00 |
DisclosureSEC source: 0001127602-21-015059 · form4.xml · derivative · entry 3 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,747 shares Expires 2022-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: This option becomes exercisable in equal installments on each of the first three anniversaries of the grant date (2/7/2012). Read SEC document |
| May 03, 2021 Filed May 4, 2021 14:45 UTC | 3M CO MMM · Entity 1275 | SaleCommon Stock | 6,803 | $197.80 | $1,345,599.39 |
DisclosureSEC source: 0001127602-21-015059 · form4.xml · nonDerivative · entry 2 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,114.5329 F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 17, 2020. F2 · balance_after: Includes shares acquired under 3M's General Employee Stock Purchase Plan. F3 · balance_after: Includes shares acquired pursuant to 3M's Dividend Reinvestment Plan. Read SEC document |
| May 03, 2021 Filed May 4, 2021 14:45 UTC | 3M CO MMM · Entity 1275 | Exercise / conversionCommon Stock | 9,747 | $87.89 | $856,663.83 |
DisclosureSEC source: 0001127602-21-015059 · form4.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,917.5329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 17, 2020. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 23:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,499 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002162 · form4-04272021_040408.xml · nonDerivative · entry 1 Roman Michael F · CIK 0001577544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,499 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 01:15 UTC | 3M CO MMM · Entity 1275 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 207,302 | $0.00 Strike: $175.02 | $0.00 |
DisclosureSEC source: 0001127602-21-003870 · form4.xml · derivative · entry 3 Roman Michael F · CIK 0001577544 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,302 Underlying: Common Stock · 207,302 shares Expires 2031-02-01 F5 · derivative.exercise_date: The stock option will vest and become exercisable in a series of three equal installments on each of the first, second and third anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.